2fak: Difference between revisions

New page: left|200px<br /><applet load="2fak" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fak, resolution 2.80Å" /> '''Crystal structure of...
 
No edit summary
Line 1: Line 1:
[[Image:2fak.gif|left|200px]]<br /><applet load="2fak" size="450" color="white" frame="true" align="right" spinBox="true"  
[[Image:2fak.gif|left|200px]]<br /><applet load="2fak" size="350" color="white" frame="true" align="right" spinBox="true"  
caption="2fak, resolution 2.80&Aring;" />
caption="2fak, resolution 2.80&Aring;" />
'''Crystal structure of Salinosporamide A in complex with the yeast 20S proteasome'''<br />
'''Crystal structure of Salinosporamide A in complex with the yeast 20S proteasome'''<br />


==Overview==
==Overview==
The crystal structures of the yeast 20S proteasome core particle (CP) in, complex with Salinosporamides A (NPI-0052; 1) and B (4) were solved at &lt;3, angstroms resolution. Each ligand is covalently bound to Thr1O(gamma) via, an ester linkage to the carbonyl derived from the beta-lactone ring of the, inhibitor. In the case of 1, nucleophilic addition to the beta-lactone, ring is followed by addition of C-3O to the chloroethyl group, giving rise, to a cyclic ether. The crystal structures were compared to that of the, omuralide/CP structure solved previously, and the collective data provide, new insights into the mechanism of inhibition and irreversible binding of, 1. Upon opening of the beta-lactone ring, C-3O assumes the position, occupied by a water molecule in the unligated enzyme and hinders, deacylation of the enzyme-ligand complex. Furthermore, the resulting, protonation state of Thr1NH2 deactivates the catalytic N-terminus.
The crystal structures of the yeast 20S proteasome core particle (CP) in complex with Salinosporamides A (NPI-0052; 1) and B (4) were solved at &lt;3 angstroms resolution. Each ligand is covalently bound to Thr1O(gamma) via an ester linkage to the carbonyl derived from the beta-lactone ring of the inhibitor. In the case of 1, nucleophilic addition to the beta-lactone ring is followed by addition of C-3O to the chloroethyl group, giving rise to a cyclic ether. The crystal structures were compared to that of the omuralide/CP structure solved previously, and the collective data provide new insights into the mechanism of inhibition and irreversible binding of 1. Upon opening of the beta-lactone ring, C-3O assumes the position occupied by a water molecule in the unligated enzyme and hinders deacylation of the enzyme-ligand complex. Furthermore, the resulting protonation state of Thr1NH2 deactivates the catalytic N-terminus.


==About this Structure==
==About this Structure==
2FAK is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Saccharomyces_cerevisiae Saccharomyces cerevisiae] with SA1 as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Proteasome_endopeptidase_complex Proteasome endopeptidase complex], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.25.1 3.4.25.1] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2FAK OCA].  
2FAK is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Saccharomyces_cerevisiae Saccharomyces cerevisiae] with <scene name='pdbligand=SA1:'>SA1</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Proteasome_endopeptidase_complex Proteasome endopeptidase complex], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.25.1 3.4.25.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FAK OCA].  


==Reference==
==Reference==
Line 15: Line 15:
[[Category: Saccharomyces cerevisiae]]
[[Category: Saccharomyces cerevisiae]]
[[Category: Groll, M.]]
[[Category: Groll, M.]]
[[Category: Potts, B.C.]]
[[Category: Potts, B C.]]
[[Category: SA1]]
[[Category: SA1]]
[[Category: drug design]]
[[Category: drug design]]
Line 23: Line 23:
[[Category: ubiquitin]]
[[Category: ubiquitin]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 10:27:22 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:19:28 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA